Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Pierre Fabre Médicament
Woman and Man Max 99 years
Pierre Fabre Médicament
Update Il y a 4 ans
Effects of OMACOR in patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome. A proof of concept study
To assess the effect of Omacor on the electrocardiographic QTc Fridericia interval in LQT3 patients (cardiac sodium channel gene SCN5A mutation leading to congenital long-QT syndrome).
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Pierre Fabre Médicament
Update Il y a 4 ans
Comparative study of the effect of 4-week treatment with ossein-hydroxyapatite compound versus calcium carbonate on bone biomarkers in young women with low calcium intake. Prospective, monocenter, randomized, open-label, two-period,cross-over trial
The main objective of this study is to compare the effect of 4-week treatment with ossein-hydroxyapatite compound versus calcium carbonate on biochemical markers of bone resorption in young women with...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pierre Fabre Médicament
Update Il y a 4 ans
ORAL VINORELBINE AND CISPLATIN WITH CONCOMITANT RADIOTHERAPY FOLLOWED BY EITHER CONSOLIDATION THERAPY WITH ORAL VINORELBINE AND CISPLATIN PLUS BEST SUPPORTIVE CARE OR BEST SUPPORTIVE CARE ALONE IN STAGE III NON SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE III STUDY
To compare progression-free survival in both arms.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pierre Fabre Médicament
Update Il y a 4 ans
Etude de l’efficacite de la dihydroergotamine par voie orale dans l’hypotension orthostatique de patients dysautonomiques
Montrer l’effet d’Ikaran® LP 5 mg dans l’hypotension orthostatique de patients dysautonomiques.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pierre Fabre Médicament
Update Il y a 4 ans
Comparative study of efficacy and safety of Structum® and Chondrosulf® in patients with symptomatic osteoarthritis of the knee.A Multicenter, Randomized, Double-Blind, Double Placebo-Controlled, Parallel Group Study
To demonstrate non-inferiority of Structum® to Chondrosulf® on pain relief and functional improvement in patients with symptomatic knee OA over 24 weeks.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pierre Fabre Médicament/Institut de Recherche Pierre Fabre
Update Il y a 4 ans
Bronchodilator properties and safety of a repeated dose of V0162 inhalation powder in asthma
To assess the bronchodilator properties of V0162 inhalation powder delivered once daily during 8 days in adult patients with asthma usually treated with ICS and LABA.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)
Update Il y a 4 ans
Effects of F17464 in acute exacerbation of schizophrenia
To evaluate the potential efficacy of 40 mg/day of oral F17464 in comparison to placebo over 6 weeks in patients with acute exacerbation of schizophrenia
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pierre Fabre Médicament
Update Il y a 4 ans
EFFICACY AND SAFETY STUDY OF THE ANTIHISTAMINE V0114CP 2.5MG IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS. RANDOMISED, DOUBLE-BLIND, THREE ARM PARALLEL GROUP STUDY INCLUDING PLACEBO AND ACTIVE CONTROL ARM (DESLORATADINE 5 MG)
to demonstrate the efficacy of a 2-week treatment by the antihistamine V0114CP 2.5 mg versus placebo in reducing symptoms during seasonal allergic rhinitis.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pierre Fabre Médicament
Update Il y a 4 ans
EFFICACY AND SAFETY STUDY OF THE ANTIHISTAMINE V0114CP 2.5MG IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS. RANDOMISED, DOUBLE-BLIND, THREE ARM PARALLEL GROUP STUDY INCLUDING PLACEBO AND ACTIVE CONTROL ARM (DESLORATADINE 5 MG)
to demonstrate the efficacy of a 2-week treatment by the antihistamine V0114CP 2,5 mgversus placebo in reducing symptoms during seasonall allergic rhinitis
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pierre Fabre Médicament - IRPF
Update Il y a 4 ans
EFFECT OF V0251 IN ACUTE VERTIGO. A RANDOMISED DOUBLE-BLIND PLACEBO CONTROLLED STUDY
The primary objective of the study is to determine the efficacy of one single intravenous injection of 4g of V0251 on vertigo symptoms relief in patient presenting with an attack of acute vertigo from...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
Next